No, Do Not Treat an Asymptomatic Patient Who Has Already Recovered
For a patient who has already recovered from pharyngitis, antibiotic treatment for group A Streptococcus is not indicated, regardless of whether the initial infection was streptococcal. The IDSA guidelines explicitly state that diagnostic testing or empiric treatment of asymptomatic individuals is not routinely recommended 1.
Key Reasoning
Asymptomatic Patients Should Not Be Treated
The 2012 IDSA guidelines provide a strong recommendation (with moderate-quality evidence) that diagnostic testing or empiric treatment of asymptomatic household contacts of patients with acute streptococcal pharyngitis is not routinely recommended 1. This principle extends to patients who were symptomatic but have now recovered—they are functionally asymptomatic at the time of presentation.
Additionally, follow-up post-treatment throat cultures or rapid antigen detection tests are not recommended routinely (strong recommendation, high-quality evidence) 1. This underscores that once symptoms have resolved, further testing or treatment serves no clinical purpose.
The Window for Benefit Has Closed
Antibiotics for confirmed GAS pharyngitis provide modest symptomatic benefit—shortening sore throat duration by only 1-2 days, with a number needed to treat of 6 at 3 days and 21 at 1 week 2. Once the patient has recovered, there is no symptomatic benefit to gain.
The primary rationale for treating GAS pharyngitis is to:
- Reduce symptom duration (already passed)
- Prevent suppurative complications like peritonsillar abscess (risk window has passed)
- Prevent acute rheumatic fever (treatment must begin within 9 days of symptom onset to be effective)
Complications Are Not Prevented After Recovery
The evidence shows antibiotics may prevent acute rheumatic fever and peritonsillar abscess when given during active infection 2. However, there is little evidence supporting prevention of acute glomerulonephritis even with timely treatment 2. More importantly, these preventive benefits require treatment during the acute phase—not after recovery.
Recent evidence from 2026 demonstrates that even aggressive testing and treatment strategies prevent remarkably few invasive GAS infections: only 6.7% in children and 2.8% in adults at best, with a number needed to treat of 12,000-110,000 to prevent one invasive case 3. This reinforces that post-recovery treatment would have negligible impact on serious complications.
Chronic Carrier Consideration
If this patient were to have persistent positive testing despite being asymptomatic, they would be classified as a chronic GAS carrier rather than having active infection. The guidelines explicitly state that antibiotics are not recommended for chronic GAS carriers because they are unlikely to spread infection and are at little or no risk for complications 2.
Clinical Pitfalls to Avoid
Do not confuse "questionable pustules" seen during the acute illness with an indication for delayed treatment. Tonsillar exudates are part of the clinical picture during active infection but do not justify treatment after recovery.
Do not test asymptomatic patients. Testing a recovered patient may identify a carrier state, leading to unnecessary antibiotic exposure without clinical benefit.
Watch for red flags suggesting complications rather than treating retrospectively. If the patient develops severe symptoms like difficulty swallowing, drooling, neck tenderness, or swelling, evaluate for suppurative complications (peritonsillar abscess, parapharyngeal abscess, Lemierre syndrome) that require urgent intervention 2.
What You Should Do Instead
Provide reassurance that:
- The typical course of pharyngitis is less than 1 week 2
- Recovery without antibiotics is the expected outcome for most cases
- Antibiotics after recovery provide no benefit and carry risks of adverse effects and antimicrobial resistance
Only consider re-evaluation if the patient develops new severe symptoms suggesting complications, not for retrospective treatment of a resolved infection.